Modified animal erythropoietin polypeptides and their uses

Patent metadata

Field	Value
Publication number	US-9644014-B2
Application number	US-201514854819-A
Country	US
Kind code	B2
Filing date	Sep 15, 2015
Priority date	Sep 26, 2008
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

Modified animal erythropoietin polypeptides and uses thereof are provided.

First claim

What is claimed is:

1. A method of treating a feline with anemia comprising administering to the feline a therapeutically-effective amount of a feline erythropoietin (fEPO) polypeptide comprising a non-naturally encoded amino acid, wherein the non-naturally encoded amino acid is substituted at a position selected from the group consisting of residues 49, 53, 76, 131, 132, and 133 of SEQ ID NO: 2, wherein the non-naturally encoded amino acid is selected from the group consisting of p-acetylphenylalanine, p-propargyl-tyrosine, m-acetylphenylalanine, O-propargyl-tyrosine, O-methyl-L-tyrosine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, L-Dopa, a fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, and an isopropyl-L-phenylalanine.

2. The method of claim 1 , wherein the non-naturally encoded amino acid is selected from the group consisting of p-acetylphenylalanine, p-propargyl-tyrosine, m-acetylphenylalanine, and O-propargyl-tyrosine.

3. The method of claim 1 , wherein the poly(ethylene glycol) moiety has a molecular weight of between about 1 kilodalton (kDa) and about 100 kDa.

4. The method of claim 1 , wherein the poly(ethylene glycol) moiety has a molecular weight of between about 1 kDa and about 50 kDa.

5. The method of claim 1 , wherein the poly(ethylene glycol) moiety has a molecular weight of between about 5 kDa and about 40 kDa.

6. The method of claim 1 , wherein said anemia is non-regenerative anemia.

7. The method of claim 1 , wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene glycol) moiety.

8. The method of claim 7 , wherein the fEPO polypeptide is substituted at a position selected from the group consisting of residues 49 and 53 of SEQ ID NO: 2.

9. The method of claim 8 , wherein the poly(ethylene glycol) moiety has a molecular weight of about 20 kDa.

10. The method of claim 8 , wherein the poly(ethylene glycol) moiety has a molecular weight of about 30 kDa.

11. The method of claim 8 , wherein the poly(ethylene glycol) moiety has a molecular weight of about 40 kDa.

12. The method of claim 8 , wherein said anemia is non-regenerative anemia.

Assignees

• Ambrx Inc
• Lilly Co Eli

Inventors

• Tian Feng
• Hays Putnam Anna-Maria A
• Song Frank
• Chu Stephanie
• Sheffer Joseph
• Barnett Richard S
• Siladi Marc
• Atkinson Kyle
• Lee Darin
• Canning Peter C

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/06

  Antianaemics · CPC title

• C07K14/505 Primary

  Erythropoietin [EPO] · CPC title

• C12N15/102

  Mutagenizing nucleic acids · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title